Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients
The primary objective is to analyze peritonitis rate and peritonitis bacteriology as risk factors for loss of residual renal function, technique failure and mortality in chronic kidney disease patients.
Secondary objectives are: To know the current rate of peritonitis in peritoneal dialysis population and to understand the bacteriological profile of peritonitis.
To know the rate and risk factors other than peritonitis involved in the loss of residual renal function.
To analyze the utility of alternative diagnostic tests, such as reagent strips, for early detection of peritonitis when traditional tests are not available.
To analyze the simultaneous measurement of serum creatinine and cystatin-C as alternative measurements of peritoneal clearance and residual renal function.
Loss of Residual Renal Function
Technique Failure in Peritoneal Dialysis
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Role of Peritonitis in the Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients|
- Loss of residual renal function [ Time Frame: 25 months ] [ Designated as safety issue: Yes ]
- Technique (peritoneal dialysis) failure [ Time Frame: 25 months ] [ Designated as safety issue: Yes ]Shift to hemodialysis
- Death [ Time Frame: 25 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||December 2013|
|Estimated Study Completion Date:||January 2016|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Incident peritoneal dialysis patients
Patients with chronic kidney disease incident to peritoneal dialysis treatment
|Contact: Ramon Paniagua, MD, PhD||+52-55-56276900 ext firstname.lastname@example.org|
|Unidad de Investigación Médica en Enfermedades Nefrológicas, Instituto Mexicano del Seguro Social||Not yet recruiting|
|Mexico City, DF, Mexico, 06722|
|Principal Investigator: Ramon Paniagua, MD, PhD|
|Sub-Investigator: Catarina Munguia-Miranda, MD|
|Sub-Investigator: Maria de Jesus Ventura-Garcia, MSc|